Sign in

CIK 0001662774

  • Non-accelerated filer
  • Smaller reporting company

IRulya Therapeutics Inc.

Sign in to watch
Ticker
IRLA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
901024039
Phone
+1 203-208-8994
Business address
101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
Former names
Quince Therapeutics, Inc., Cortexyme, Inc.
  1. 4 Open-market buy Director bought 67,881 shares at an average $1.02 ($69,233)
  2. 4 Open-market buy Director bought 57,369 shares at an average $1.01 ($58,134)
  3. 4 Open-market buy Director bought 43,134 shares at an average $0.94 ($40,546)
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 3 Insider Initial Statement of Ownership
  7. 4 Derivatives Options or other derivatives
  8. 3 Insider Initial Statement of Ownership
  9. 4 Derivatives Options or other derivatives
  10. 3 Insider Initial Statement of Ownership
  11. 4 Open-market buy Director bought 82,052 shares at an average $1.32 ($107,898)
  12. 4 Open-market buy Director bought 250,000 shares at an average $1.30 ($325,737)
  13. 4 Open-market buy Chief Executive Officer bought 88,000 shares at $1.26 ($110,880)
  14. 4 Open-market buy Chief Executive Officer bought 80,000 shares at $1.24 ($99,200)
  15. 4 Open-market buy Chief Business Officer bought 71,762 shares at $1.22 ($87,550)
  16. 4 Open-market buy Director bought 8,000 shares at $1.23 ($9,840)
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 4 of 11 · 211 filings